[en] BACKGROUND: Invasion and angiogenesis are major hallmarks of glioblastoma (GBM) growth. While invasive tumor cells grow adjacent to blood vessels in normal brain tissue, tumor cells within neovascularized regions exhibit hypoxic stress and promote angiogenesis. The distinct microenvironments likely differentially affect metabolic processes within the tumor cells. METHODS: In the present study, we analyzed gene expression and metabolic changes in a human GBM xenograft model that displayed invasive and angiogenic phenotypes. In addition, we used glioma patient biopsies to confirm the results from the xenograft model. RESULTS: We demonstrate that the angiogenic switch in our xenograft model is linked to a proneural-to-mesenchymal transition that is associated with upregulation of the transcription factors BHLHE40, CEBPB, and STAT3. Metabolic analyses revealed that angiogenic xenografts employed higher rates of glycolysis compared with invasive xenografts. Likewise, patient biopsies exhibited higher expression of the glycolytic enzyme lactate dehydrogenase A and glucose transporter 1 in hypoxic areas compared with the invasive edge and lower-grade tumors. Analysis of the mitochondrial respiratory chain showed reduction of complex I in angiogenic xenografts and hypoxic regions of GBM samples compared with invasive xenografts, nonhypoxic GBM regions, and lower-grade tumors. In vitro hypoxia experiments additionally revealed metabolic adaptation of invasive tumor cells, which increased lactate production under long-term hypoxia. CONCLUSIONS: The use of glycolysis versus mitochondrial respiration for energy production within human GBM tumors is highly dependent on the specific microenvironment. The metabolic adaptability of GBM cells highlights the difficulty of targeting one specific metabolic pathway for effective therapeutic intervention.
Disciplines :
Oncology
Author, co-author :
Talasila, Krishna M; Department of Biomedicine, University of Bergen, Norway. ; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway.
Røsland, Gro V; Department of Biomedicine, University of Bergen, Norway.
Hagland, Hanne R; Department of Biomedicine, University of Bergen, Norway.
Eskilsson, Eskil; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Flønes, Irene H; Department of Neurology, Haukeland University Hospital, Bergen, Norway.
FRITAH, Sabrina ; NorLux Neuro-oncology Laboratory, Luxembourg Institute of Health, Luxembourg.
AZUAJE, Francisco ; NorLux Neuro-oncology Laboratory, Luxembourg Institute of Health, Luxembourg.
Atai, Nadia; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, The Netherlands.
Harter, Patrick N; Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
MITTELBRONN, Michel ; Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Andersen, Michael; Department of Pathology, Haukeland University Hospital, Bergen, Norway.
Joseph, Justin V; Department of Biomedicine, University of Bergen, Norway. ; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway.
Hossain, Jubayer Al; Department of Biomedicine, University of Bergen, Norway. ; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway. ; Department of Pathology, Haukeland University Hospital, Bergen, Norway.
Vallar, Laurent; Department of Oncology, Luxembourg Institute of Health, Luxembourg.
Noorden, Cornelis J F van; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, The Netherlands.
NICLOU, Simone P. ; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway. ; NorLux Neuro-oncology Laboratory, Luxembourg Institute of Health, Luxembourg.
Thorsen, Frits; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway. ; Molecular Imaging Center, Department of Biomedicine, University of Bergen, Norway.
Tronstad, Karl Johan; Department of Biomedicine, University of Bergen, Norway.
Tzoulis, Charalampos; Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Bjerkvig, Rolf; Department of Biomedicine, University of Bergen, Norway. ; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway. ; Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Miletic, Hrvoje; Department of Biomedicine, University of Bergen, Norway. ; KG Jebsen Brain Tumor Research Centre, University of Bergen, Norway. ; Department of Pathology, Haukeland University Hospital, Bergen, Norway.
Louis D, Ohgaki H, Wiestler O, et al. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.
Zeng W, Liu P, Pan W, et al. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015;356(2 Pt A):263-267.
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-337.
Marin-Valencia I, Yang C, Mashimo T, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827-837.
Navis AC, Niclou S P, Fack F, et al. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG. Acta Neuropathol Commun. 2013;1(1):18.
Talasila KM, Soentgerath A, Euskirchen P, et al. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013;125(5):683-698.
Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
Madhavan S, Zenklusen JC, Kotliarov Y, et al. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res.: MCR. 2009;7(2):157-167.
Bjerkvig R, Tonnesen A, Laerum OD, et al. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990;72(3):463-475.
Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263-267.
Sakariassen PO, Prestegarden L, Wang J, et al. Angiogenesisindependent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A. 2006;103(44):16466-16471.
Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70(10):4163-4173.
Perez-Llamas C, Lopez-Bigas N. Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS One. 2011;6(5):e19541.
Wang J, Duncan D, Shi Z, et al. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(Web Server issue):W77-83.
Supek F, Bosnjak M, Skunca N, et al. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6(7):e21800.
Sun J, Gong X, Purow B, et al. Uncovering microRNA and transcription factor mediated regulatory networks in glioblastoma. PLoS Comput Biol. 2012;8(7):e1002488.
Cline MS, Smoot M, Cerami E, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2(10):2366-2382.
Huttenhower C, Haley EM, Hibbs MA, et al. Exploring the human genome with functional maps. Genome Res. 2009;19(6):1093-1106.
Baumgarten P, Harter PN, Tonjes M, et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40(2):205-216.
Molenaar RJ, Botman D, Smits MA, et al. Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant Inhibitor AGI-5198. Cancer Res. 2015;75(22):4790-4802.
Yang Y, Balcarcel RR. 96-well plate assay for sublethal metabolic activity. Assay Drug Dev Technol. 2004;2(4):353-361.
Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260-264.
Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463(7279):318-325.
Cooper LA, Gutman DA, Chisolm C, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012;180(5):2108-2119.
Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313-326.
Zhou Y, Zhou Y, Shingu T, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286(37):32843-32853.
Jelluma N, Yang X, Stokoe D, et al. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res: MCR. 2006;4(5):319-330.
Deighton RF, Le Bihan T, Martin SF, et al. Interactions among mitochondrial proteins altered in glioblastoma. J Neurooncol. 2014;118(2):247-256.
Iommarini L, Calvaruso MA, Kurelac I, et al. Complex I impairment in mitochondrial diseases and cancer: parallel roads leading to different outcomes. Int J Biochem Cell Biol. 2013;45(1):47-63.
Barrientos A, Moraes CT. Titrating the effects of mitochondrial complex I impairment in the cell physiology. J Biol Chem. 1999;274(23):16188-16197.
Hagland H, Nikolaisen J, Hodneland LI, et al. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opin Ther Targets. 2007;11(8):1055-1069.
Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986-7993.
Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011;108(9):3749-3754.
Beckner ME, Chen X, An J, et al. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest. 2005;85(3):316-327.
Wang J, Miletic H, Sakariassen PO, et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer. 2009;9:465.
Shiraishi T, Verdone JE, Huang J, et al. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget. 2015;6(1):130-143.
Beckner ME, Stracke ML, Liotta LA, et al. Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst. 1990;82(23):1836-1840.
Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
Li J, Taich ZJ, Goyal A, et al. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget. 2014;5(17):7342-7356.
Talasila KM, Brekka N, Mangseth K, et al. Tumor versus stromal cells in culture-survival of the fttest? PLoS One. 2013;8(12):e81183.
Halliday J, Helmy K, Pattwell SS, et al. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci U S A. 2014;111(14):5248-5253.
Bhat K P, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24(3):331-346.
Piao Y, Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19(16):4392-4403.
Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014;26(2):288-300.
Murat A, Migliavacca E, Hussain SF, et al. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009;4(6):e5947.
Naef F, Huelsken J. Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks. Nucleic Acids Res. 2005;33(13):e111.
